Medical News

RSS

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

13 Sep 2010

PDL BioPharma announces conversion rate adjustment for Convertible Senior Notes due 2012

PDL BioPharma, Inc. today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) effective September 16, 2010 in connection with the special dividend to be paid on October 1, 2010 to all stockholders who own shares of PDL on September 15, 2010, the record date.

13 Sep 2010

XenoPort intends to initiate Phase 3 XP19986 trial for multiple sclerosis

XenoPort, Inc. announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

13 Sep 2010

Daiichi Sankyo receives marketing approval for Inavir in Japan

Biota Holdings Limited today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® in Japan. Inavir® is Daiichi Sankyo's brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.

13 Sep 2010

First Edition: September 13, 2010

In this morning's news, many in Congress are pushing for repeal of a tax provision in the health law that critics say places a heavy burden on small businesses. Meanwhile, opponents of the overhaul are focused on a Florida court hearing.

13 Sep 2010

Sebelius to discuss Obama Administration's efforts to combat AIDS epidemic in America

On Monday, September 13, U.S. Department of Health and Human Services Secretary Kathleen Sebelius will address approximately 3,000 HIV/AIDS activists and advocates at the United States Conference on AIDS (USCA) in Orlando, Florida, the largest AIDS-related gathering in the country.

13 Sep 2010

Passport Health announces keynote speaker for Rethink Africa

Passport Health, the nation's largest private provider of travel medical services and immunizations, in conjunction with the Mid-Atlantic Chapter of the Africa Travel Association, and Loyola University Maryland's Sellinger School of Business and Management officially announced John McDonough, Secretary of State of MD as the keynote speaker for Rethink Africa.

13 Sep 2010

New book relates mercury in vaccines to autism

The U.S. government revealed last week that they will compensate a family millions of dollars for their daughter's injury related to her infant vaccines that contained mercury and the subsequent development of autism. Yet, the CDC continues to tell the public that there is no connection between vaccines and autism and that the mercury has been removed, although the flu shot recommended for all pregnant women, infants, and children continues to be preserved with mercury.

13 Sep 2010

AHIMA releases recommendations to HHS Office of Civil Rights

While AHIMA continues to applaud federal government support for the ideal of protecting patients' health information rights, the proposed rule making for HIPAA privacy, security and enforcement by HHS has a number of requirements that we do not believe the industry is ready to undertake; especially as it gears up for Meaningful Use. Today AHIMA is releasing its recommendations to the HHS Office of Civil Rights (OCR) that speak to the issues we believe are most critical to the patients of America, the healthcare industry and the best practice of health information management.

13 Sep 2010

Heart Failure Society of America's 14th Annual Scientific Meeting convenes September 12, 2010

The Heart Failure Society of America (HFSA) 14th Annual Scientific Meeting convened Sunday, September 12, 2010 at the San Diego Convention Center in San Diego. This four-day meeting -- a forum for heart failure specialists to present research findings and advances in treatment -- will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.

13 Sep 2010

DRC to supply information technology services, medical program support to WRAMC

Dynamics Research Corporation, a leading provider of innovative management consulting, engineering, and technology solutions to federal and state governments, today announced that it was awarded a new task order with the Walter Reed Army Medical Center.

13 Sep 2010

LORENZ Life Sciences announces final agenda for userBridge.10 conference

LORENZ Life Sciences Group, the largest supplier of eCTDs in the world, announced the final agenda for userBridge.10, their well-established user's conference, taking place this year from September 21st-23rd in Frankfurt, Germany.

13 Sep 2010

Genes behind aggregation of arsenic in plants

In many countries arsenic in food is a major problem. But researchers at the University of Skövde in Sweden have now identified two genes that may play a crucial role in how arsenic is stored in plants.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Genzyme Corporation enters into asset purchase agreement with LabCorp

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.

13 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

JDRF selects Convio's Common Ground CRM for primary constituent relationship management

Convio, Inc. announced today that Juvenile Diabetes Research Foundation (JDRF) has selected Convio as their standard for constituent relationship management (CRM), online marketing and fundraising, and special events for JDRF's national headquarters and all chapters. JDRF will use Convio's integrated, on-demand marketing, fundraising and advocacy suite to power and support their efforts to engage constituents and raise money.

13 Sep 2010

LabCorp acquires Genzyme Genetics for $925 million

Laboratory Corporation of America Holdings, today announced that it has entered into a definitive agreement under which LabCorp will acquire Genzyme Genetics, a business unit of Genzyme Corp., in an all cash transaction valued at $925 million. Net of expected income tax benefits, less acquisition related expenses, the acquisition has a net cash cost to LabCorp of approximately $795 million.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled "Compositions and Methods of Vascular Injury Repair." The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in treating or repairing a vascular injury following an acute myocardial infarction (AMI), and delivery of the cell therapy.

13 Sep 2010